MAPrc’s researchers are currently working on a number of projects investigating new diagnostic and treatment methods for people experiencing depression

The following projects are currently recruiting participants. Please contact us if you wish to receive futher information or take part in a project.

Metformin for mind & metabolism
This is a 12 week randomised control trial to determine whether metformin improves mood, improves cognition and causes weight loss in women and men with co-morbid treatment resistant depression and abdominal obesity. Men and women aged 18-65 with major depressive disorder who are taking an antidepressant and still experiencing some depressive symptoms, and also have abdominal obesity are invited to participate. Participants will be randomly allocated to receive either 2000mg/day metformin or placebo. Participants will be assessed by a study researcher every four weeks to monitor depressive symptoms and weight, and cognition will be assessed initially and at conclusion of the trial. Unwanted side effects will also be monitored for. For more information, please contact Chen Chen Bian on or 9076 6564
Tibolone and Escitalopram in Perimenopausal Depression
Clinical trials of a hormone treatment called Tibolone, for the treatment of depression in peri and post menopause. To take part in this study you must be physically well, aged 45-65 be experiencing depression and able to give informed consent. For further details click here or contact Emmy Gavrilidis on 9076 6564 or email 
Transcranial magnetic stimulation (TMS) for depression
TMS uses magnetic pulses to change activity in the areas of the brain thought to be related to this illness, and is being investigated as an alternative treatment for people, who have not responded to antidepressant medication, are experiencing the depressive phase of bipolar disorder, or who developed depression following a head injury. For further information click here or contact the TMS team on 90766595 or email
Magnetic Seizure Therapy (MST) for depression
MST uses a magnetic field to induce a seizure for therapeutic purposes, and is being investigated as an alternative to Electroconvulsive therapy for severe depression. For further information click here or contact Dr. Kate Hoy on 9076 5034 or email    
Deep Brain Stimulation for depression
Deep Brain Stimulation involves the precise implantation of very small electrodes into specific areas of the brain, in an attempt to change activity in those and related areas and improve the symptoms of very severe, treatment resistant depression.
As DBS is considered a treatment of last resort, only individuals who have trialled all less invasive antidepressant treatments and remained severely depressed can be considered for the procedure, This means having trialled multiple medications for all antidepressant drug classes, combinations of antidepressant medications, cognitive behavioural therapy, transcranial magnetic stimulation and extensive electroconvulsive therapy (ECT).
At MAPrc we have been investigating the use of DBS for the treatment of severe treatment resistant depression for a number of years and have recently finished recruitment for a small inital pilot study. Analysis of the results of this study are currently underway and we are applying for funding to conduct a larger and longer term investigation. 
Whilst we seek further funding, we are not actively evaluating new patients for this procedure. However if you wish to be considered for the program in the future, and you have tried all of the treatments listed above, you can have your psychiatrist send a detailed referral letter to Dr Rebecca Segrave at .
This will be kept on record and if the program recommences in the future you will be contacted. 
EVestG (ElectrovestibuloGraphy)
A new technique, EVestG (ElectrovestibuloGraphy) in being investigated as a possible objective method for diagnosing participants with depression. For further information click here or contact MAPrc on 9076 6564 or email 
Little is known about how to treat depression and most depressed individuals often take a number of medications to find out which medication best suits them. iSPOT-D is a large international study to find out who will respond to which antidepressant. The principal aim is to get the prescription right the first time. You may be eligible if you are aged 18–65 and have already been diagnosed or suspect you have depression. The study involves two testing sessions and seven telephone check-ins within 12 months. You will also provide a blood sample to the researchers and receive treatment from you own doctor. Participants will be reimbursed for their time.  For further information click here or contact Mirjana Stojkovic on    
Mood and Oral Contraceptives 
An observational study of women taking / not taking hormonal contraception (i.e. COCP, POP, Implanon, DMPA) exploring current mood & risk and resistance factors for adverse mood change. To take part in this study you must be a female 18 years of age or older, able to give informed consent and not currently pregnant, breast-feeding or menopausal. For further information click here or contact Emmy Gavrilidis on 9076 6913 or email  
NRAMP - National Register of Antipsychotic Medication in Pregnancy
An observational study for women who are taking or have taken antipsychotic medications during their pregnancy. For further information click here or contact Heather Gilbert 9076 6591 or email 
Brain function and neurological health
A neuroimaging study using functional magnetic resonance imaging (fMRI) and electroencephalography (EEG), in conjunction with cognitive testing and blood biomarkers, to look at the emotional brain function and neurological health in depression. For further information click here or contact Peter Goodin on 0425 798 610 or email       
Auditory verbal hallucinations
 A large-scale phenomenological study investigating the physical characteristics as well as underlying beliefs related to auditory verbal hallucinations, also known as 'voice-hearing' experiences, in diverse clinicial populations, including bipolar disorder, major depression and schizophrenia, as well as non-clinical groups. For further information click here or contact Dr Wei Lin Toh on 9076 5712 or 



 MAPrc Monash Alfred Psychiatry Research Centre, Level 4, 607 St Kilda Road, Melbourne 3004

 © MAPrc 2013. Designed and hosted by Infoxchange Australia